UroGen Pharma Ltd. (URGN) has a negative trailing P/E of -6.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 23.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.87%, forward earnings yield 4.27%. PEG 0.25 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -86.2 | 0.89 | 10.26 | 9.55 | - |
| 2017 | -18.8 | -0.02 | 5.48 | 46.02 | - |
| 2018 | -9.0 | -0.07 | 7.53 | 601.40 | - |
| 2019 | -6.5 | -3.13 | 3.80 | 38,057.98 | - |
| 2020 | -3.1 | -0.15 | 4.07 | 33.26 | - |
| 2021 | -1.9 | 0.12 | 25.26 | 4.42 | - |
| 2022 | -1.8 | 0.54 | -2.26 | 3.14 | - |
| 2023 | -4.2 | 0.16 | -6.63 | 5.23 | - |
| 2024 | -3.6 | 0.22 | -51.87 | 5.05 | - |
| 2025 | -7.3 | -0.94 | -10.68 | 10.26 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.16 | $17.53M | $-1.94M | -11.1% |
| 2017 | $-2.06 | $8.16M | $-20M | -245.2% |
| 2018 | $-4.80 | $1.13M | $-75.66M | -6707.2% |
| 2019 | $-4.90 | $18K | $-100.53M | -558500% |
| 2020 | $-5.90 | $11.8M | $-128.48M | -1088.9% |
| 2021 | $-4.96 | $48.04M | $-110.82M | -230.7% |
| 2022 | $-4.79 | $64.36M | $-109.16M | -169.6% |
| 2023 | $-3.55 | $82.71M | $-102.24M | -123.6% |
| 2024 | $-2.96 | $90.4M | $-126.87M | -140.4% |
| 2025 | $-3.19 | $109.79M | $-153.49M | -139.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.17 | $-1.87 – $-0.23 | $244.52M | $221.66M – $268.77M | 6 |
| 2027 | $0.92 | $0.52 – $1.23 | $425.02M | $403.42M – $453.98M | 6 |
| 2028 | $2.17 | $0.02 – $3.03 | $545.15M | $545.15M – $545.15M | 5 |
| 2029 | $4.96 | $4.16 – $6.15 | $784.18M | $687.76M – $929.51M | 1 |
| 2030 | $6.62 | $5.56 – $8.21 | $1B | $878.32M – $1.19B | 1 |
